Bausch Health Cos Free Cash Flow 2012-2026 | BHC
Bausch Health Cos free cash flow from 2012 to 2026. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
| Bausch Health Cos Annual Free Cash Flow | |
|---|---|
| 2025 | |
| 2024 | 1,260.00 |
| 2023 | 817.00 |
| 2022 | -946.00 |
| 2021 | 1,826.00 |
| 2020 | 830.00 |
| 2019 | 1,276.00 |
| 2018 | 1,378.00 |
| 2017 | 5,372.00 |
| 2016 | 2,051.00 |
| 2015 | 2,035.00 |
| 2014 | 3,512.00 |
| 2013 | 967.80 |
| 2012 | 641.00 |
| 2011 | 617.96 |
| Bausch Health Cos Quarterly Free Cash Flow | |
|---|---|
| 2026-03-31 | |
| 2025-12-31 | |
| 2025-09-30 | 600.00 |
| 2025-06-30 | 286.00 |
| 2025-03-31 | 96.00 |
| 2024-12-31 | 1,260.00 |
| 2024-09-30 | 765.00 |
| 2024-06-30 | 431.00 |
| 2024-03-31 | 129.00 |
| 2023-12-31 | 817.00 |
| 2023-09-30 | 525.00 |
| 2023-06-30 | 285.00 |
| 2023-03-31 | 107.00 |
| 2022-12-31 | -946.00 |
| 2022-09-30 | -1,355.00 |
| 2022-06-30 | -38.00 |
| 2022-03-31 | -109.00 |
| 2021-12-31 | 1,826.00 |
| 2021-09-30 | 1,880.00 |
| 2021-06-30 | 735.00 |
| 2021-03-31 | 381.00 |
| 2020-12-31 | 830.00 |
| 2020-09-30 | 495.00 |
| 2020-06-30 | 341.00 |
| 2020-03-31 | 210.00 |
| 2019-12-31 | 1,276.00 |
| 2019-09-30 | 1,119.00 |
| 2019-06-30 | 676.00 |
| 2019-03-31 | 391.00 |
| 2018-12-31 | 1,378.00 |
| 2018-09-30 | 1,119.00 |
| 2018-06-30 | 591.00 |
| 2018-03-31 | 397.00 |
| 2017-12-31 | 5,372.00 |
| 2017-09-30 | 4,657.00 |
| 2017-06-30 | 1,147.00 |
| 2017-03-31 | 916.00 |
| 2016-12-31 | 2,051.00 |
| 2016-09-30 | 1,525.00 |
| 2016-06-30 | 988.00 |
| 2016-03-31 | 495.00 |
| 2015-12-31 | 2,035.00 |
| 2015-09-30 | 1,498.90 |
| 2015-06-30 | 789.00 |
| 2015-03-31 | 425.30 |
| 2014-12-31 | 3,512.00 |
| 2014-09-30 | 2,747.60 |
| 2014-06-30 | 688.70 |
| 2014-03-31 | 426.20 |
| 2013-12-31 | 967.80 |
| 2013-09-30 | 737.80 |
| 2013-06-30 | 561.00 |
| 2013-03-31 | 249.70 |
| 2012-12-31 | 641.00 |
| 2012-09-30 | 583.84 |
| 2012-06-30 | 463.37 |
| 2012-03-31 | 222.36 |
| 2011-12-31 | 617.96 |
| 2011-09-30 | 443.13 |
| 2011-06-30 | 279.01 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $2.086B | $10.266B |
| Bausch Health Companies Inc. develops, manufactures and markets a wide array of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products along with medical devices such as contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices in the therapeutic areas of eye-health, gastroenterology (GI), and dermatology. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |